Andrew Hantel1,2, Clark DuMontier3,4, Oreofe O Odejide1,5, Marlise R Luskin5, Adam S Sperling5, Tammy Hshieh3, Richard Chen1, Robert Soiffer5, Jane A Driver3,6, Gregory A Abel1,5. 1. Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Division of Inpatient Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Division of Aging, Brigham and Women's Hospital, Boston, Massachusetts. 4. Marcus Institute for Aging Research, Boston, Massachusetts. 5. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts. 6. New England Geriatric Research and Educational Center, VA Boston Healthcare System, Boston, Massachusetts.
Abstract
BACKGROUND: Brief measures of physical function such as gait speed may be useful to optimize treatment intensity for older adults who have blood cancer; however, little is known about whether such assessments are already captured within oncologists' "gestalt" assessments. METHODS: Gait speed was assessed in 782 patients ≥75 years of age who had blood cancer, with results reported to providers after treatment decisions were made; 408 patients required treatment when different intensities were available per National Comprehensive Cancer Network (NCCN) guidelines. We performed structured abstractions of treatment intensity recommendations into standard intensity, reduced intensity, or supportive care, based on NCCN guidelines. We modeled gait speed and survival using Cox regression and performed ordinal logistic regression to assess predictors of NCCN-based categorizations of oncologists' treatment intensity recommendations, including gait speed. RESULTS: The median survival by gait speed category was 10.8 months (<0.4 m/s), 18.6 months (0.4-0.6 m/s), 34.0 months (0.6-0.8 m/s), and unreached (>0.8 m/s). Univariable hazard ratios (HRs) for death increased for each lower category compared with ≥0.8 m/s (0.6-0.8 m/s: HR, 1.76; 0.4-0.6 m/s: HR, 2.30; <0.4 m/s: HR, 3.31). Gait speed predicted survival in multivariable Cox regression (all P < .05). In multivariable models including age, sex, and Eastern Cooperative Oncology Group performance status, gait speed did not predict oncologists' recommended treatment intensity (all P > .05) and did not add to a base model predicting recommended treatment intensity. CONCLUSION: In older adults with blood cancer who presented for treatment, gait speed predicted survival but not treatment intensity recommendation. Incorporating gait speed into decision making may improve optimal treatment selection.
BACKGROUND: Brief measures of physical function such as gait speed may be useful to optimize treatment intensity for older adults who have blood cancer; however, little is known about whether such assessments are already captured within oncologists' "gestalt" assessments. METHODS: Gait speed was assessed in 782 patients ≥75 years of age who had blood cancer, with results reported to providers after treatment decisions were made; 408 patients required treatment when different intensities were available per National Comprehensive Cancer Network (NCCN) guidelines. We performed structured abstractions of treatment intensity recommendations into standard intensity, reduced intensity, or supportive care, based on NCCN guidelines. We modeled gait speed and survival using Cox regression and performed ordinal logistic regression to assess predictors of NCCN-based categorizations of oncologists' treatment intensity recommendations, including gait speed. RESULTS: The median survival by gait speed category was 10.8 months (<0.4 m/s), 18.6 months (0.4-0.6 m/s), 34.0 months (0.6-0.8 m/s), and unreached (>0.8 m/s). Univariable hazard ratios (HRs) for death increased for each lower category compared with ≥0.8 m/s (0.6-0.8 m/s: HR, 1.76; 0.4-0.6 m/s: HR, 2.30; <0.4 m/s: HR, 3.31). Gait speed predicted survival in multivariable Cox regression (all P < .05). In multivariable models including age, sex, and Eastern Cooperative Oncology Group performance status, gait speed did not predict oncologists' recommended treatment intensity (all P > .05) and did not add to a base model predicting recommended treatment intensity. CONCLUSION: In older adults with blood cancer who presented for treatment, gait speed predicted survival but not treatment intensity recommendation. Incorporating gait speed into decision making may improve optimal treatment selection.
Authors: Stephanie Studenski; Subashan Perera; Kushang Patel; Caterina Rosano; Kimberly Faulkner; Marco Inzitari; Jennifer Brach; Julie Chandler; Peggy Cawthon; Elizabeth Barrett Connor; Michael Nevitt; Marjolein Visser; Stephen Kritchevsky; Stefania Badinelli; Tamara Harris; Anne B Newman; Jane Cauley; Luigi Ferrucci; Jack Guralnik Journal: JAMA Date: 2011-01-05 Impact factor: 56.272
Authors: Anays Murillo; Angel M Cronin; Jacob P Laubach; Tammy T Hshieh; Anna M Tanasijevic; Paul G Richardson; Jane A Driver; Gregory A Abel Journal: J Geriatr Oncol Date: 2018-11-22 Impact factor: 3.599
Authors: Melissa Y Wei; Mohammed U Kabeto; Kenneth M Langa; Kenneth J Mukamal Journal: J Gerontol A Biol Sci Med Sci Date: 2018-01-16 Impact factor: 6.053
Authors: Susan E Hardy; Subashan Perera; Yazan F Roumani; Julie M Chandler; Stephanie A Studenski Journal: J Am Geriatr Soc Date: 2007-10-03 Impact factor: 5.562
Authors: Yuji Nishiwaki; Elizabeth Breeze; Liam Smeeth; Christopher J Bulpitt; Ruth Peters; Astrid E Fletcher Journal: Am J Epidemiol Date: 2004-10-15 Impact factor: 4.897